Related Experiment Video
Updated: Feb 10, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Recent advances in understanding and managing retinal vein occlusions
Daniel D Esmaili1, David S Boyer1,2
1Retina-Vitreous Associates Medical Group, 001 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA.
Anti-vascular endothelial growth factor (anti-VEGF) agents are now preferred for treating retinal vein occlusions, offering better safety and efficacy than older methods. Newer treatments like dexamethasone implants also show promise for retinal vein occlusion management.
Area of Science:
- Ophthalmology
- Retinal Vascular Diseases
Background:
- Retinal vein occlusions (RVOs) are a significant cause of vision loss.
- Historically, laser treatment and intravitreal triamcinolone acetonide were standard care for RVOs.
Purpose of the Study:
- To review the evolving treatment landscape for retinal vein occlusions.
- To highlight the efficacy and safety of newer therapeutic agents.
Main Methods:
- Review of recent clinical studies and treatment guidelines for RVOs.
- Comparison of anti-VEGF agents, corticosteroids, and historical treatments.
Main Results:
- Anti-vascular endothelial growth factor (anti-VEGF) agents demonstrate superior safety and efficacy for both branch and central RVOs.
- Laser photocoagulation is now primarily indicated for neovascular complications, not macular edema.
- Intravitreal dexamethasone implants and suprachoroidal triamcinolone show potential as viable RVO treatments.
Conclusions:
- Anti-VEGF therapy represents a significant advancement in RVO management.
- Emerging corticosteroid treatments offer alternative therapeutic options for RVOs.
More Related Videos
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Understanding the Self
Understanding Self-Concept
Understanding Deception
Understanding Love
Understanding Consciousness
Sleep, a crucial state, is characterized by reduced...

